EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Progress in the Development of Selective MAGL Modulators (2020–2026)

Eva Landucci iD, Chiara Lonzi iD, Tommaso Bonomo iD, Simone Bertini iD, Marco Macchia, Carlotta Granchi iD, Giulia Bononi iD

Molecules · 03.07.2026 · 31 (13) · 2353

DOI: 10.3390/molecules31132353 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 03.07.2026. Verfasst von Eva Landucci und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy. Hauptthemen laut MEDLINE: Monoacylglycerol Lipases, Enzyme Inhibitors. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoacylglycerol lipase (MAGL) is a key enzyme at the interface between the endocannabinoid system and lipid metabolism, playing a pivotal role in the hydrolysis of the endocannabinoid 2-arachidonoylglycerol and in the regulation of lipid mediators involved in inflammation, pain, neurodegeneration and cancer. Owing to its therapeutic relevance, MAGL has emerged as an attractive pharmacological target, stimulating extensive research efforts aimed at the development of potent and selective modulators of its activity. Advances in medicinal chemistry, together with the increasing application of innovative computational approaches and biochemical methods to assess MAGL activity, have significantly expanded the chemical space of compounds capable of modulating this enzyme. This review provides a comprehensive overview of selective MAGL modulators reported in the scientific literature from 2020 to the present, excluding compounds described exclusively in patent literature and MAGL probes, as this area has been recently reviewed elsewhere, ranging from classical enzyme inhibitors to modulators acting through alternative strategies, such as targeted protein degradation. Overall, this review highlights the structural diversity and the main strategies that have emerged in recent years in modulating MAGL and it aims to guide the rational design of next-generation MAGL-targeting agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Monoacylglycerol LipasesEnzyme InhibitorsHumansAnimalsLipid MetabolismEndocannabinoids

Stichwörter der Autor:innen

MAGLMAGL degradersMAGL inhibitorsMAGL modulatorsanti-MAGL PROTACsmonoacylglycerol lipase

Substanzen

Monoacylglycerol LipasesEnzyme InhibitorsEndocannabinoids

Autor:innen und Institutionen

  • Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
  • Department of Life Sciences, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.

ORCID-Profile: Eva Landucci, Chiara Lonzi, Tommaso Bonomo, Simone Bertini, Carlotta Granchi, Giulia Bononi

Zitieren

APA

Landucci, E., Lonzi, C., Bonomo, T., Bertini, S., Macchia, M., Granchi, C., & Bononi, G. (2026). Recent Progress in the Development of Selective MAGL Modulators (2020–2026). Molecules, 31(13), 2353. https://doi.org/10.3390/molecules31132353

Vancouver

Landucci E, Lonzi C, Bonomo T, Bertini S, Macchia M, Granchi C, et al. Recent Progress in the Development of Selective MAGL Modulators (2020–2026). Molecules. 2026;31(13):2353. doi:10.3390/molecules31132353

BibTeX
@article{Landucci2026,
  author = {Landucci, Eva and Lonzi, Chiara and Bonomo, Tommaso and Bertini, Simone and Macchia, Marco and Granchi, Carlotta and Bononi, Giulia},
  title = {Recent Progress in the Development of Selective MAGL Modulators (2020–2026)},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {13},
  pages = {2353},
  doi = {10.3390/molecules31132353}
}
Kostenlos starten →